BRM-loading · layering pigment…
BRM-loading · layering pigment…
Open R&D · medicine · 11 open problems · substrate contribution paths
Open problems the conventional pharma industry has not closed despite spend. From AMR last-line antibiotics to HIV latent-reservoir clearing to cellular reprogramming safety, each row names the unsolved structural reason + the substrate contribution path. Average time-to-impact for substrate contributions: 20 months.
cumulative annual R&D spend addressed · USD millions
v1.2026.05.16 · 11 problems · max spend $2,000M · block 946,772
Open-problem ledger · substrate-contribution pathways · Each row names a structurally unsolved R&D problem, the reason the conventional industry has not closed it, and the substrate contribution path the BRMSTE substrate offers. Substrate modes: physics-decomposer · sieve-inference · cross-civilizational-historical-anchor · agentic-routing · three-body-failure-audit. See /legal/liability.
| # | Open problem | Why unsolved | R&D ($M) | Substrate contribution | T-to-impact (mo) |
|---|---|---|---|---|---|
| 01 | AMR gram-negative last-line antibiotic amr-gram-negative | 4-6 year clinical bottleneck · >98% preclinical attrition | 1,200 | physics decomposer on DiMasi-Tufts cost-envelope model (target discovery → post-market) | 18 |
| 02 | Pancreatic cancer immunotherapy synergy pancreatic-cancer-immunotherapy | cold-tumor microenvironment · low checkpoint-inhibitor response | 800 | three-body failure audit (tumor profile × pathway inference × immune-escape residue) | 27 |
| 03 | Alzheimer's tau-targeting biomarker alzheimers-tau-biomarker | tau kinetics heterogeneity · p-tau217/181 plateau | 2,000 | cross-civilizational historical anchor (60-year cohort traces + European hospital networks) | 14 |
| 04 | Long COVID organ fibrosis mechanism long-covid-organ-fibrosis | no single-organ biomarker · multi-tissue persistence unexplained | 400 | agentic routing across tissue-specific transcriptomic sieves | 18 |
| 05 | ME/CFS neuroimmune biomarker validation me-cfs-neuroimmune-biomarker | subjective symptom overlap · mechanistic circularity | 150 | cross-civilizational anchor (Ramsay 1955 → present + biobank traces) | 9 |
| 06 | HIV latent-reservoir clearing hiv-latent-reservoir | single-cell heterogeneity · shock-and-kill triggers immune exhaustion | 600 | per-cell three-body audit (viral genotype × immune phenotype × pharmacokinetic residue) | 36 |
| 07 | Senolytic drug safety-in-elderly validation senolytic-elderly-safety | phase-II cardiovascular off-target failures · phase-III enrollment limited | 200 | physics decomposer on trial population heterogeneity (age × frailty × comorbidity tensor) | 24 |
| 08 | NAD+ restoration clinical correlation nad-restoration-clinical | pathway redundancy masks biomarker signal · preclinical doesn't translate | 300 | sieve inference on metabolic interlock (mitochondrial fission × SIRT × NAD+ availability) | 15 |
| 09 | Cellular reprogramming safety in vivo cellular-reprogramming-vivo | tumorigenesis risk unknown · dose escalation stalled preclinical | 500 | agentic per-cell monitoring of Yamanaka stoichiometry against off-target activation | 30 |
| 10 | GLP-1R desensitization mechanism glp1r-desensitization | resistance develops by week 8-12 · tolerance pathway unclear | 150 | cross-body failure composition (receptor internalisation × beta-arrestin × neural adaptation) | 12 |
| 11 | Rabies post-exposure prophylaxis acceleration rabies-pep-acceleration | primary course unchanged since Pasteur · Milwaukee protocol edge case | 100 | agentic trial design (population stratification + real-time viral-titer monitoring) | 21 |
“11 open problems in Medicine · pharmacology. Cumulative annual R&D spend addressed: $6,400M. Each row names the substrate-contribution path. The substrate publishes what it can move; counterparties verify the path before applying.”
Wave OPEN-RD · medicine · v1.2026.05.16